CalciMedica (CALC) news

Calcmedica: One-for-five reverse stock split

CalciMedica, Inc. (CALC) has announced that shareholders have approved a one-for-five reverse stock split, a move aimed at meeting listing requirements and improving the stock's marketability. The reverse split will reduce the number of outstanding shares, effectively increasing the per-share…

Calcimedica - proceeds to support Phase 1b Auxora study in PAH and CM5480 IND clearance, data expected mid-2027

Calcimedic - anticipates cash runway into second half of 2027 with upfront proceeds

Calcimedica announces private placement financing for up to approximately $49 million to advance pulmonary hypertension program

Calcimedica - FDA provides no comments, Calcimedica to continue Auxora development across indications

CalciMedica (Nasdaq: CALC) has announced that it will continue the development of its lead product candidate, Auxora™, across multiple indications following the absence of comments from the U.S. Food and Drug Administration (FDA) on its proposed pivotal program in acute pancreatitis (AP) and…